HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Abdominal obesity metabolic syndrome

AOMS1 not included

Also Known As:

Abdominal Obesity-Metabolic Syndrome

Networked: 14 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Disease Context: Research Results

Nutritional and Metabolic Diseases: 15
- Metabolic Diseases: 10142
  - Metabolic Syndrome: 29798
    - Abdominal obesity metabolic syndrome: 14
  - Glucose Metabolism Disorders: 375
    - Hyperinsulinism: 9517
      - Insulin Resistance: 84236
        Metabolic Syndrome: 29798
        Abdominal obesity metabolic syndrome: 14

Related Diseases

1.	Dyslipidemias (Dyslipidemia)
2.	Hypertension (High Blood Pressure)
3.	Insulin Resistance
4.	Cardiovascular Diseases (Cardiovascular Disease)
5.	Systemic Vasculitis

Experts

1.	Kim, Min-Sun: 1 article (06/2022)
2.	Nguyen, Hai Duc: 1 article (06/2022)
3.	Oh, Hojin: 1 article (06/2022)
4.	Higano, Celestia S: 1 article (12/2020)
5.	Asadi, Nadia: 1 article (01/2020)
6.	Aydın, Memduha: 1 article (01/2020)
7.	Bastard, Jean-Philippe: 1 article (01/2020)
8.	Capeau, Jacqueline: 1 article (01/2020)
9.	Charchour, Rim: 1 article (01/2020)
10.	Collet, Christine: 1 article (01/2020)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Abdominal obesity metabolic syndrome:

1.	AdipokinesIBA 01/01/2020 - "Metabolic abnormalities such as diabetes, dyslipidemia, abdominal obesity, metabolic syndrome, and abnormal levels of plasma adipokines have been observed in patients with schizophrenia. " 05/01/2007 - "Data were generated from a search of the PubMed database using the terms 'abdominal obesity', 'metabolic syndrome', 'insulin resistance', 'adipokines', 'interleukin-6 (IL-6)', 'adiponectin', 'tumour necrosis factor-alpha (TNF-alpha)' and 'cardiovascular disease'. "
2.	AdiponectinIBA 01/01/2020 - "The level of adiponectin is reduced in situations of insulin resistance and is negatively associated with several pathophysiological situations including abdominal obesity, metabolic syndrome, steatosis and non-alcoholic steatohepatitis, type 2 diabetes, some cancers and cognitive diseases. " 05/01/2007 - "Data were generated from a search of the PubMed database using the terms 'abdominal obesity', 'metabolic syndrome', 'insulin resistance', 'adipokines', 'interleukin-6 (IL-6)', 'adiponectin', 'tumour necrosis factor-alpha (TNF-alpha)' and 'cardiovascular disease'. "
3.	Triglycerides (Triacylglycerol)IBA 03/01/2008 - "Various factors that are thought to contribute to this rising epidemic include urbanization of rural areas, large-scale migration of rural population to urban areas, increase in sedentary lifestyle, abdominal obesity, metabolic syndrome, diabetes, inadequate consumption of fruits and vegetables, increased use of fried, processed and fast foods, tobacco abuse, poor awareness and control of CAD risk factors, unique dyslipidemia (high triglycerides, low HDL-cholesterol levels), and possible genetic predisposition due to lipoprotein (a) [Lp(a)] excess. " 06/01/2022 - "Several pathways ("SREBF and miR33 in cholesterol," "estrogen receptor pathway and lipid homeostasis," and "regulation of PGC-1α"), "negative regulation of hepatocyte apoptotic process," "negative regulation of sequestering of triglycerides," "regulation of hepatocyte apoptotic process," and "negative regulation of cholesterol storage," and "abdominal obesity metabolic syndrome" were identified as key molecular mechanisms that may be affected by mixed chemicals and implicated in the development of dyslipidemia. "
4.	LipidsIBA 01/01/2020 - "The patients' demographic and clinical data such as age, sex, abdominal obesity, metabolic syndrome, diabetes, hypertension, CRP, hepatic steatosis, blood pressure, serum uric acid (UA), lipid and creatinine were collected for analysis. " 06/01/2022 - "Several pathways ("SREBF and miR33 in cholesterol," "estrogen receptor pathway and lipid homeostasis," and "regulation of PGC-1α"), "negative regulation of hepatocyte apoptotic process," "negative regulation of sequestering of triglycerides," "regulation of hepatocyte apoptotic process," and "negative regulation of cholesterol storage," and "abdominal obesity metabolic syndrome" were identified as key molecular mechanisms that may be affected by mixed chemicals and implicated in the development of dyslipidemia. "
5.	C-Reactive ProteinIBA 06/01/2011 - "High-sensitivity C-reactive protein (hsCRP) levels are closely associated with abdominal obesity, metabolic syndrome, and atherosclerotic cardiovascular disease. " 02/01/2013 - "Diabetes, hypertension, dyslipidemia, abdominal obesity (metabolic syndrome), impaired renal function, persistent proteinuria and increased production of C-reactive protein are common risk factors for premature atherosclerosis in patients with systemic vasculitis. "
6.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/01/2014 - "This review shows that the discovery and diagnosis of diabetes during statin therapy are limited to patients with multiple pre-existing diabetogenic risk factors, including sedentary lifestyle, diabetogenic and obesogenic diet, abdominal obesity, metabolic syndrome, hypertension, family history of diabetes, dysglycemia, prediabetes, and unrecognized diabetes. "
7.	Lipoprotein(a)IBA 03/01/2008 - "Various factors that are thought to contribute to this rising epidemic include urbanization of rural areas, large-scale migration of rural population to urban areas, increase in sedentary lifestyle, abdominal obesity, metabolic syndrome, diabetes, inadequate consumption of fruits and vegetables, increased use of fried, processed and fast foods, tobacco abuse, poor awareness and control of CAD risk factors, unique dyslipidemia (high triglycerides, low HDL-cholesterol levels), and possible genetic predisposition due to lipoprotein (a) [Lp(a)] excess. "
8.	Uric Acid (Urate)IBA 01/01/2020 - "The patients' demographic and clinical data such as age, sex, abdominal obesity, metabolic syndrome, diabetes, hypertension, CRP, hepatic steatosis, blood pressure, serum uric acid (UA), lipid and creatinine were collected for analysis. "
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/01/2007 - "Data were generated from a search of the PubMed database using the terms 'abdominal obesity', 'metabolic syndrome', 'insulin resistance', 'adipokines', 'interleukin-6 (IL-6)', 'adiponectin', 'tumour necrosis factor-alpha (TNF-alpha)' and 'cardiovascular disease'. "
10.	SaltsIBA 05/01/2012 - "Uncontrolled BP was associated with males, dyslipidemia, diabetes, abdominal obesity, metabolic syndrome, always having salty food and salts added for seasoning. "

Therapies and Procedures

1.	Glycemic Control 12/01/2016 - "BS procedures have been associated with significant reduction in abdominal obesity, metabolic syndrome components, and glycemic control requiring fewer medications. "
2.	Therapeutics 04/01/2014 - "This review shows that the discovery and diagnosis of diabetes during statin therapy are limited to patients with multiple pre-existing diabetogenic risk factors, including sedentary lifestyle, diabetogenic and obesogenic diet, abdominal obesity, metabolic syndrome, hypertension, family history of diabetes, dysglycemia, prediabetes, and unrecognized diabetes. "